MindBio Therapeutics Moves Toward Commercial Deployment of AI Voice Analysis for Impairment Detection in Mining Sector

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing toward commercial deployment of its voice-based artificial intelligence platform for detecting drug and alcohol impairment, with an initial focus on industrial safety applications in South America's mining sector, according to a recent article.

The biotechnology company has appointed Chilean policy specialist Felipe Leyton to lead commercialization efforts in the region, signaling a transition from technology development to field implementation in large enterprise environments. Leyton brings extensive experience in national drug policy and workplace safety, having helped design and implement Chile's 'Zero Tolerance' alcohol-impaired driving law as part of the country's alcohol prevention framework. He also played a role in establishing Chile's roadside drug testing program introduced in 2019.

Leyton's appointment reflects MindBio's strategy of aligning technical development with regulatory and industry expertise in markets where impairment detection is closely tied to workplace safety and compliance requirements. The company's AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. MindBio is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication in a range of enterprise environments, including mining, aviation, construction, and law enforcement.

The move into South America's mining sector is significant because mining operations often occur in remote and hazardous environments where impairment can lead to serious accidents. By deploying voice-based AI, companies can conduct non-invasive, rapid impairment tests without requiring specialized equipment or personnel, potentially reducing workplace incidents and enhancing safety compliance. The technology also has implications for broader industrial safety, as it can be adapted for use in other sectors like aviation and construction.

MindBio's focus on South America aligns with the region's growing emphasis on workplace safety and drug testing. Chile, in particular, has stringent regulations regarding alcohol and drug use in the workplace, making it an ideal market for such technology. Leyton's background in shaping national policies on impairment detection positions him to navigate regulatory landscapes and build partnerships with mining companies seeking to enhance safety protocols.

The full article discussing MindBio's commercialization efforts is available at https://ibn.fm/JBNVq. For the latest news and updates relating to MBQIF, visit the company’s newsroom at https://ibn.fm/MBQIF.